DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS

Compounds of formula I: I are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive dis...

Full description

Saved in:
Bibliographic Details
Main Authors HERMAN, Lee W, HARDY, Larry Wendell, BROWN, Scott P, HEFFERNAN, Michele L.R
Format Patent
LanguageEnglish
French
Published 08.02.2018
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Compounds of formula I: I are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases. L'invention concerne des composés de formule I : I, ainsi que des compositions pharmaceutiques contenant de tels composés. L'invention concerne également des méthodes de traitement de troubles neurologiques ou psychiatriques chez un patient nécessitant un tel traitement. De tels troubles comprennent la dépression, le trouble bipolaire, la douleur, la schizophrénie, le trouble obsessionnel compulsif, la toxicomanie, le trouble social, le trouble d'hyperactivité avec déficit de l'attention, un trouble de l'anxiété, l'autisme, un trouble cognitif, ou un symptôme neuropsychiatrique tel que l'apathie, la dépression, l'anxiété, la psychose, l'agressivité, l'agitation, les troubles du contrôle des impulsions et les troubles du sommeil dans les troubles neurologiques tels que la maladie d'Alzheimer et la maladie de Parkinson.
Bibliography:Application Number: WO2016US45559